Infantile spasms therapeutics are used for the treatment of seizures or an epilepsy syndrome in young children, usually aged one year or below. Infantile spasm refers to sudden stiffening of the body, the arms, and the legs or forward bending of the head. Primary treatments for infantile spams include steroid therapy and an anti-seizure medicine called Sabril. Infantile spasms are also known as the West syndrome, as the disease was first defined by Dr. William James West in the 1840s. These spasms generally begin in the first year of life, between three and eight months of age, and occur in two to three out of every 10,000 babies. The disorder is more common in boys than girls. Family history is another cause about 3% to 6% of cases can be linked to family history. The diagnosis of infantile spasms is carried out by physical and neurological examination, laboratory tests such as MRI of the brain, and blood and urine tests. Medication includes monotherapy as well as combination therapy. In approximately 20%50% of the patients, infantile spasms evolve into the Lennox-Gastaut syndrome. Conversely, a similar percentage of patients with the Lennox-Gastaut syndrome have a history of infantile spasms
This report elaborates the market size, market characteristics, and market growth of the Infantile Spasms Therapeutics industry, and breaks down according to the type, application, and consumption area of Infantile Spasms Therapeutics. The report also conducted a PESTEL analysis of the industry to study the main influencing factors and entry barriers of the industry.

In Chapter 3.4 of the report, the impact of the COVID-19 outbreak on the industry was fully assessed. Fully risk assessment and industry recommendations were made for Infantile Spasms Therapeutics in a special period. This chapter also compares the markets of Pre COVID-19 and Post COVID-19.
In addition, chapters 8-12 consider the impact of COVID-19 on the regional economy.

Key players in the global Infantile Spasms Therapeutics market covered in Chapter 13:
INSYS Therapeutics
Anavex Life Sciences
ORPHELIA Pharma
Valerion Therapeutics
Mallinckrodt Pharmaceuticals
H. Lundbeck
GW Pharmaceuticals
Retrophin
Catalyst Pharmaceuticals

In Chapter 6, on the basis of types, the Infantile Spasms Therapeutics market from 2015 to 2025 is primarily split into:
Monotherapy
Combination Therapy

In Chapter 7, on the basis of applications, the Infantile Spasms Therapeutics market from 2015 to 2025 covers:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Geographically, the detailed analysis of production, trade of the following countries is covered in Chapter 4.2, 5:
United States
Europe
China
Japan
India

Geographically, the detailed analysis of consumption, revenue, market share and growth rate of the following regions are covered in Chapter 8, 9, 10, 11, 12:
North America (Covered in Chapter 8)
United States
Canada
Mexico
Europe (Covered in Chapter 9)
Germany
UK
France
Italy
Spain
Others
Asia-Pacific (Covered in Chapter 10)
China
Japan
India
South Korea
Southeast Asia
Others
Middle East and Africa (Covered in Chapter 11)
Saudi Arabia
UAE
South Africa
Others
South America (Covered in Chapter 12)
Brazil
Others

Years considered for this report:
Historical Years: 2015-2019
Base Year: 2019
Estimated Year: 2020
Forecast Period: 2020-2025